Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/16 10:00:00 pm
91.65 USD   -2.57%
01/13 CONCERT PHARMAC : Incyte prevails in patent challenge for blockbuste..
01/11 NASDAQ 100 MOVE : Incy, myl
01/10 S&P 500 ANALYST : Incy
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on INCYTE CORPORATION
01/13 CONCERT PHARMACEUTICALS : Incyte prevails in patent challenge for blockbuster dr..
01/11 NASDAQ 100 MOVERS : Incy, myl
01/10 S&P 500 ANALYST MOVES : Incy
01/08 Celgene gets JAK-2 inhibitor in Impact deal
01/08 INCYTE : Delaware-based Incyte, Massachusetts company announce R&D agreement
01/05 INCYTE : Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
2017 INCYTE : U.S. Patents Awarded to Inventors in Delaware (Dec. 28)
2017 INCYTE : Merus Announces the U.S. Court of Appeals for the Federal Circuit Denie..
2017 NEWLINK GENETICS : Inhibiting IDO could slow TB disease progression
2017 INCYTE : to Present at Upcoming Investor Conference
2017 Aduro discontinues development of CRS-207
2017 INCYTE CORPORATION : (INCY) Position Boosted by Capital Bank & Trust Co
2017 INCYTE : Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi®..
2017 INCYTE : Study shows Incyte's Jakafi is effective in long-term treatment of rare..
2017 IMMUNOVACCINE : Immuno-Oncology Candidate Yields `Impressive` Early Clinical Res..
2017 MACROGENICS : Announces Closing of MGA012 Global Collaboration and License Agree..
2017 IMMUNOVACCINE : Announces Positive Clinical Data from Its Collaborative Combinat..
2017 IMMUNOVACCINE : to Hold Webcast and Conference Call to Discuss Clinical Data Fro..
2017 NASDAQ 100 MOVERS : Nclh, incy
2017 NASDAQ 100 MOVERS : Incy, msft
2017 INCYTE : Announces Initiation of Pivotal Clinical Trial of Ruxolitinib Jakafi® f..
2017 INCYTE CORPORATION : Today’s Research Reports on Trending Tickers: Incyte Corpor..
2017 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Amendments to Articles of Incorp..
2017 INCYTE CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, F..
2017 INCYTE : Study Results from Incyte Corporation Update Understanding of Organic R..
2017 INCYTE : Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) ..
2017 Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Pe..
2017 INCYTE : Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®)..
2017 Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
2017 BRISTOL MYERS SQUIBB : Myers posts early checkpoint combination data on fast-adv..
2017 ELI LILLY AND : Lilly to Present New Data on Immunology Portfolio at ACR/ARHP An..
2017 INCYTE : and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Can..
2017 CALITHERA BIOSCIENCES : Reports Third Quarter 2017 Financial Results and Recent ..
2017 LILLY, INCYTE : Baricitinib Shows Greater Improvements In Pain Control In RA
2017 INCYTE : to Present at Upcoming Investor Conference
2017 INCYTE : and MacroGenics Announce Global Collaboration and Licensing Agreement f..
2017 ASTRAZENECA : and Incyte enter clinical trial collaboration in early lung cancer
2017 INCYTE : More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio ..
2017 INCYTE CORPORATION : Today's Research Reports on Stocks to Watch: Incyte Corpora..
2017 INCYTE : and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Can..
2017 INCYTE : PhIII dealmaking frenzy in i/o continues as AstraZeneca follows PACIFIC..
2017 ASTRAZENECA : and Incyte enter clinical trial collaboration in early lung cancer..
2017 ASTRAZENECA : plans new pivotal lung cancer trial
2017 ASTRAZENECA : and Incyte to assess new lung cancer regimen
2017 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
2017 INCYTE CORPORATION : to Host Earnings Call
2017 INCYTE : tops Street 3Q forecasts
2017 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
2017 INCYTE : Reports 2017 Third-Quarter Financial Results and Updates on Key Clinica..
2017 INCYTE : and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Can..
2017 INCYTE : AstraZeneca announce trial of drug combination
2017 INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
2017 INCYTE : Names New Member to Its Board of Directors
2017 MACROGENICS, INC. (NASDAQ : MGNX) Files An 8-K Entry into a Material Definitive ..
2017 INCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
2017 CONCERT PHARMACEUTICALS : Announces PTAB Denies Incyte Petition Challenging CTP-..
2017INCYTE CORPORATION : quaterly earnings release
2017 INCYTE : Microgenics strike deal, valued at up to $900 million, for cancer-fight..
2017 BIOTECH MOVERS : MacroGenics, Inc. (NASDAQ:MGNX) And PTC Therapeutics, Inc. (NAS..
2017 INCYTE : grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
2017 INCYTE : to Present at Upcoming Investor Conference
2017 CONCERT PHARMACEUTICALS : Announces PTAB Denies Incyte Petition Challenging CTP ..
2017 INCYTE : Microgenics strike deal, valued at up to $900 million, for cancer-fight..
2017 CALITHERA BIOSCIENCES : Announces First Patient Treated in Phase 1 Cohort of INC..
2017 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
2017 IBD Announces First Annual Biotech Innovator Awards
2017 INCYTE : to Report Third Quarter Financial Results
2017 NEXTERA ENERGY : Natixis Asset Management Has Lifted Its Incyte Corp. (INCY) Hol..
2017 NASDAQ 100 MOVERS : Cost, incy
2017 INCYTE : and Cancer Support Community Delaware Announce the Establishment of the..
2017 INCYTE : Health
2017 INCYTE : Merus Intellectual Property Portfolio Expands with Two New Patents For ..
2017 ALEXION PHARMACEUTICALS : Adds Paul A. Friedman, M.D. To Its Board of Directors
2017 ALEXION PHARMACEUTICALS, INC. (NASDA : ALXN) Files An 8-K Departure of Directors..
2017 INCYTE : Supports the Myeloproliferative Neoplasm MPN Community During Blood Can..
1  2  3  4  5  6  7Next
Financials ($)
Sales 2017 1 503 M
EBIT 2017 -215 M
Net income 2017 -228 M
Finance 2017 494 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 511,81
EV / Sales 2017 12,9x
EV / Sales 2018 10,8x
Capitalization 19 852 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 143 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Lothar H. Finke Head-Clinical Development & General Manager-Japan
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-0.68%19 852
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.42%20 432
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692
NEKTAR THERAPEUTICS20.56%11 338